Glioblastoma Therapeutics Network (GTN; U19 Clinical Trial Required)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 15, 2026
Can you apply?
This grant is for researchers and institutions conducting clinical trials in glioblastoma therapeutics. Eligible applicants typically include NIH-recognized research institutions, medical centers, and universities with strong oncology programs. The program funds collaborative research networks and multi-site clinical trial consortiums. Institutions must have the infrastructure, staffing, and experience to conduct rigorous clinical trials in neuro-oncology.
Applicants must demonstrate established relationships with patient populations and experience managing complex multi-institutional research agreements. Foreign institutions may apply if they have U.S. partnerships. Your institution should have prior federal research funding history and institutional review board capabilities.
This mechanism is specifically designed for U19 cooperative agreements supporting networked clinical research. Standard NIH eligibility requirements apply, including proper institutional documentation and authorized signing officials.
Not the right fit? Find grants for your organization in 5 questions →
Key dates
- Sep 17, 2025 Applications open
- May 27, 2026 Application deadline
- Mar 5, 2027 Award announced
- Mar 5, 2027 Project start
Program description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms.
To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through IND studies, into pilot clinical studies in humans. Appropriate therapeutic agents include: (1) novel agents or (2) agents or combinations approved for other indications and repurposed for treatment of GBM following appropriate preclinical studies. The scope of the NOFO, from late pre-clinical through early (Phase 0/1) clinical studies, uniquely spans a gap in the GBM drug development process.
Who can apply
Eligible applicants
How to apply
Application links
Key dates & requirements
Required documents
- SF-424 (Application for Federal Assistance)
- Research Plan/Project Narrative
- Budget and Budget Justification
- Institutional signing official documentation
- Multi-institutional agreements and commitment letters
- Biographical sketches of key personnel
- Data management and quality assurance plan
- IRB/Ethics approval letters
Program contact
- 👤 Suzanne Forry, Ph.D.
- 📧 forryscs@mail.nih.gov
- 📞 240-276-5922
Funding track record
Recent awards under CFDA 93.394 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$67,679,289
-
$42,479,238
-
$38,139,324
-
$37,552,767
-
$36,939,788
-
$35,037,695
-
$30,393,940
-
$30,179,102
-
$18,390,244
-
$18,143,614
Top States by Funding
- PA 10 awards $135.7M
- WA 7 awards $122.3M
- CA 12 awards $108.0M
- TX 8 awards $92.9M
- OH 5 awards $73.2M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.394). How funding has trended year over year.
| 2024 | $540,918,671 | |
| 2025 | $602,293,691 | |
| 2026 est. | $716,748,079 |
FAQ
Who can apply for this grant?
Research institutions, universities, medical centers, and hospitals with established oncology or neuro-oncology programs. Applicants must have experience managing multi-site clinical trials.
What types of activities does this grant fund?
Clinical trials testing new glioblastoma therapeutics, research network development, and patient enrollment infrastructure. It supports collaborative research across multiple institutions.
Is this a one-time award or multi-year?
U19 mechanisms are typically multi-year cooperative agreements. Funding is subject to annual renewal based on progress.
How competitive is this grant?
Very competitive. This is a clinical trial-required mechanism with rigorous scientific review. Strong preliminary data and established research teams are essential.
What is the typical funding range?
U19 awards typically range from $500,000 to $2 million annually depending on scope. Actual amounts vary by review and budget justification.
💡 Tips for applicants
- Build your application around a clearly defined clinical research question with strong scientific rationale for the proposed therapeutic approach.
- Demonstrate robust multi-institutional collaboration with signed commitment letters from all participating sites and clear governance structures.
- Include detailed patient enrollment projections with evidence of access to glioblastoma patient populations across your network.
- Develop a comprehensive data management and quality assurance plan that addresses the complexity of multi-site clinical trials.
- Show prior success with federal grants and clinical trial management through your institution's track record and team credentials.
⚠️ Common mistakes
Weak enrollment plans or unrealistic patient recruitment projections across multiple sites. Unclear governance structure for multi-institutional collaboration without formal agreements. Insufficient preliminary data or weak scientific rationale for the proposed therapeutic approach.
Similar grants
- OPEN Metastasis Research Network (U54 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required) — National Institutes of Health
- OPEN Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) — National Institutes of Health
- OPEN Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 – Clinical Trial Optional) — National Institutes of Health
- OPEN Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) — National Institutes of Health